Repligen Announces Plans To Initiate A Phase 2b Trial For RG2417 In Bipolar Disorder
Repligen Corporation (Nasdaq: RGEN) announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar disorder later this year. This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day for eight-weeks.
